1678P - A new chemotherapy-based combination to prevent osteosarcoma progression

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Bone Sarcomas
Translational Research
Presenter Morgane Monchanin
Citation Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390
Authors M. Monchanin1, P. Berchard2, M. Vienne1, J.B. Langlois3, N. Gadot4, A. Bernet5, J. Blay6, A. Dutour7
  • 1Equipe C. Caux Et J.y Blay, CRCL, 69373 - Lyon Cedex/FR
  • 2Equipe C. Caux Et J.y Blay, CRCL, 69373 - Lyon Cedex /FR
  • 3In Vivo Imaging, CERMEP, 69677 - BRON/FR
  • 4Anipath Platform, CRCL, 69373 - Lyon Cedex /FR
  • 5Apoptosis And Cancer, CRCL, 69373 - Lyon Cedex /FR
  • 6Département D'oncologie Médicale Adulte, Centre Léon Bérard, 69008 - Lyon/FR
  • 7Crcl, Centre Léon Bérard, 69008 - Lyon/FR

Abstract

Background

Despite the intensification of chemotherapy regimen, 5 years survival rates for patients with metastatic or relapsed osteosarcoma (OS) remains of 20%. The secreted factor netrin 1 (Nt1) is overexpressed in many human cancers to block apoptosis. Recent studies showed that blocking Nt1 interaction with its receptors potentiates chemotherapy efficacy suggesting that combining chemotherapies with Nt1 interference could be a promising approach for chemoresistant tumors like OS.

Methods

Analyses of the ATGSarc database (http://atg-sarc.sarcomabcb.org/), indicate that Sarcoma with complex genomic (SCG) with a higher expression of Nt1 have a poorer outcome (p 

Results

As pre operative treatment, Dox/aNt1 combination caused a marked delay in OS progression (median end point reached at day 17 and day 22 respectively in Dox and Dox/aNt1 group, (p  5mm) were found respectively in 75% and 17% of Dox and Dox/aNt1 treated rats As post operative treatment, Dox/aNt1combination significantly increased animals survival (median end point reached at day 15 and day 21 respectively in Dox and in Dox/aNt1 group; (p 

Conclusions

Our study reporting the antiproliferative and antimetastatic effects and of Dox/aNt1 Combination in OS indicate that this combined treatment could be a way to overcome OS chemoresistance.

Clinical trial identification

Legal entity responsible for the study

Dutour Aurélie

Funding

None

Disclosure

All authors have declared no conflicts of interest.